F8 and hemophilia A: End point: Treated annualized bleed rate (ABR) in Hemophilia A patients without FVIII inhibitors, for emicizumab (1.5 mg/kg weekly, 3 mg/kg biweekly) vs. no prophylaxis (SAP Section 2.3.1)